BenchSci

Canvas Category Software : Special Purpose : Pharmaceutical

Primary Location Toronto, Ontario, Canada

Financial Status VC-C

BenchSci empowers scientists with the world’s most advanced biomedical AI to advance assets with fewer, more successful experiments,

Assembly Line

BenchSci Raises $95 Million Series D Funding to Enable Drug Discovery Innovation at Scale With its Groundbreaking AI Platform ASCEND

📅 Date: May 25, 2023

🔖 Topics: Funding Event

🏢 Organizations: BenchSci, Generation Investment Management

BenchSci, a world leader in AI solutions for preclinical life sciences research and development (R&D), today announced a $95 million (US $70 million) Series D funding round led by Generation Investment Management, with participation from existing investors iNovia Capital, TCV, Golden Ventures and F-Prime Capital. The most recent funding brings BenchSci’s total funds raised to $218 million (US $170 million).

The funds will be used to expand the company’s revolutionary AI drug discovery platform, ASCEND™ by BenchSci, which enables scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early. ASCEND users from BenchSci’s top 10 customers were able to uncover novel targets and disease indications in 22% of key projects and reduced unnecessary experimentation by 40%, contributing to a new era of more efficient, AI-driven drug discovery.